Non-penetrating filtering surgery with MMC

Article

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control.

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control, according to Esther Arranz-Marquez and co-workers from the Vissum Corporacion Oftalmologica de Madrid, Spain.

A prospective trial enrolled 131 patients with primary open angle glaucoma (POAG) to undergo non-penetrating filtering surgery with MMC and without an implant. Patients were followed-up at one day and one, three, six, nine and 12 months postoperatively.

Mean preoperative IOP was 20.2±5.2 mmHg. At each follow-up a reduction in IOP was recorded (p=0.001): 12.3±4.2, 13.7±4.6, 13.7±3.6, 14.2±4.0, 14.1±3.6 at one, three, six, nine and 12 months, respectively. Further, the mean number of medications reduced from 1.8±0.7 to 0.1±0.4 12 months postoperatively. Goniopuncture was carried out in 31 eyes and three eyes were re-operated on due to inadequate IOP control.

At the study's conclusion, the authors believed that this procedure offers reasonable IOP control with few postoperative complications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.